Cora Capital Advisors’s Pfizer PFE Stock Holding History

Cora Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,052	Closed	-$201K	–	96
2023 Q3	$201K	Buy	+6,052	New	+$214K	0.13%	87
2023 Q2	–	Sell	-5,742	Closed	-$234K	–	96
2023 Q1	$234K	Buy	5,742 +102	+2%	+$4.41K	0.17%	79
2022 Q4	$289K	Buy	+5,640	New	+$270K	0.2%	59

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Cora Capital Advisors's PFE Position: Q4 2023 in Review

Cora Capital Advisors sold out of Pfizer (PFE) in Q4 2023, closing a stake of 6,052 shares — an estimated $201K sold.

Cora Capital Advisors first reported a position in PFE in Q4 2022 and held it in 3 quarters. The position peaked at $289K in Q4 2022. 2,936 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

Cora Capital Advisors reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
Cora Capital Advisors sold 6,052 Pfizer shares in Q4 2023, an estimated $201K.
Cora Capital Advisors first reported a position in Pfizer in Q4 2022 and held it in 3 quarters.
Cora Capital Advisors's Pfizer position peaked at $289K in Q4 2022.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Cora Capital Advisors's 13F filing for Q4 2023, filed 5 Feb 2024.